• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era.

作者信息

Tao Qing-Qing, Lin Rong-Rong, Wu Zhi-Ying

机构信息

Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, People's Republic of China.

MOE Frontier Science Center for Brain Science and Brain-Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, People's Republic of China.

出版信息

Clin Interv Aging. 2023 Mar 6;18:353-358. doi: 10.2147/CIA.S394821. eCollection 2023.

DOI:10.2147/CIA.S394821
PMID:36911809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10001034/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d1/10001034/5da9d67aba55/CIA-18-353-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d1/10001034/5da9d67aba55/CIA-18-353-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d1/10001034/5da9d67aba55/CIA-18-353-g0001.jpg

相似文献

1
Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era.阿尔茨海默病的早期诊断：迈向基于血液生物标志物的时代。
Clin Interv Aging. 2023 Mar 6;18:353-358. doi: 10.2147/CIA.S394821. eCollection 2023.
2
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.血浆 tau 蛋白、神经丝轻链和淀粉样 β 水平与痴呆风险：一项基于人群的队列研究。
Brain. 2020 Apr 1;143(4):1220-1232. doi: 10.1093/brain/awaa054.
3
Biomarkers for the early diagnosis of Alzheimer's disease.用于阿尔茨海默病早期诊断的生物标志物。
Lancet Neurol. 2006 Mar;5(3):198-9. doi: 10.1016/S1474-4422(06)70357-X.
4
[Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].[当前临床实践中阿尔茨海默病的脑脊液生物标志物]
Rev Med Suisse. 2016 Apr 20;12(515):791-4.
5
[Biomarkers of Alzheimer disease].[阿尔茨海默病的生物标志物]
Przegl Lek. 2014;71(2):98-101.
6
Biological markers of Alzheimer's disease.阿尔茨海默病的生物标志物。
Arq Neuropsiquiatr. 2014 Mar;72(3):227-31. doi: 10.1590/0004-282x20130233.
7
Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.脑脊液生物标志物在前驱期阿尔茨海默病诊断中的作用。
Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48.
8
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.在结构化的五阶段研发框架背景下，脑脊液β淀粉样蛋白42（Aβ42）、tau蛋白和磷酸化tau蛋白作为阿尔茨海默病生物标志物的临床有效性
Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034.
9
Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.用于阿尔茨海默病的流动生物标志物：从研究工具到常规临床诊断。
Mol Neurodegener. 2021 Feb 19;16(1):10. doi: 10.1186/s13024-021-00430-x.
10
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.用于诊断阿尔茨海默病的脑脊液生物标志物：β-淀粉样蛋白（1-42）、tau蛋白、磷酸化tau-181蛋白和总蛋白。
Drugs Today (Barc). 2007 Jun;43(6):423-31. doi: 10.1358/dot.2007.43.6.1067341.

引用本文的文献

1
Genetics and Epigenetics of Alzheimer's Disease: Understanding Pathogenesis and Exploring Therapeutic Potential.阿尔茨海默病的遗传学与表观遗传学：理解发病机制与探索治疗潜力
J Mol Neurosci. 2025 May 30;75(2):72. doi: 10.1007/s12031-025-02363-2.
2
Relationships between blood pressure indicators and fluid biomarkers of brain aging in functionally intact older adults.功能正常的老年人血压指标与脑老化的流体生物标志物之间的关系。
Alzheimers Res Ther. 2025 Apr 21;17(1):85. doi: 10.1186/s13195-025-01731-9.
3
Relationships between blood pressure indicators and fluid biomarkers of brain aging in functionally intact older adults.

本文引用的文献

1
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.阿尔茨海默病协会关于阿尔茨海默病血液生物标志物的合理使用建议。
Alzheimers Dement. 2022 Dec;18(12):2669-2686. doi: 10.1002/alz.12756. Epub 2022 Jul 31.
2
Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症患者血浆中磷酸化 tau181 水平升高。
Ann Neurol. 2022 Nov;92(5):807-818. doi: 10.1002/ana.26462. Epub 2022 Aug 17.
3
Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.
功能正常的老年人血压指标与脑老化液体生物标志物之间的关系。
Res Sq. 2025 Mar 26:rs.3.rs-6018137. doi: 10.21203/rs.3.rs-6018137/v1.
4
Unlocking early detection of Alzheimer's disease: The emerging role of nanomaterial-based optical sensors.解锁阿尔茨海默病的早期检测：基于纳米材料的光学传感器的新兴作用。
J Food Drug Anal. 2024 Sep 13;32(3):296-324. doi: 10.38212/2224-6614.3520.
5
Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics.探索阿尔茨海默病生物标志物领域：基于体液的诊断方法全面分析。
Cells. 2024 Nov 18;13(22):1901. doi: 10.3390/cells13221901.
6
Assessing polyomic risk to predict Alzheimer's disease using a machine learning model.使用机器学习模型评估多组学风险以预测阿尔茨海默病。
Alzheimers Dement. 2024 Dec;20(12):8700-8714. doi: 10.1002/alz.14319. Epub 2024 Nov 7.
7
Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics.阿尔茨海默病：有效诊断与治疗的当前趋势综述
Front Aging Neurosci. 2024 Aug 9;16:1429211. doi: 10.3389/fnagi.2024.1429211. eCollection 2024.
8
Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers.使用[11C]PBB3对疑似阿尔茨海默病和额颞叶痴呆患者进行探索性Tau PET/CT：一项与PET成像和脑脊液生物标志物相关性的初步研究
Biomedicines. 2024 Jul 1;12(7):1460. doi: 10.3390/biomedicines12071460.
9
Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice.早期抑制磷酸二酯酶 4B（PDE4B）可增强 APPswe/PS1dE9 小鼠的认知弹性。
Cells. 2024 Jun 8;13(12):1000. doi: 10.3390/cells13121000.
10
Identifying Progression-Specific Alzheimer's Subtypes Using Multimodal Transformer.使用多模态变压器识别特定进展的阿尔茨海默病亚型
J Pers Med. 2024 Apr 15;14(4):421. doi: 10.3390/jpm14040421.
淀粉样蛋白-β错误折叠和 GFAP 可预测 17 年内临床阿尔茨海默病诊断的风险。
Alzheimers Dement. 2023 Mar;19(3):1020-1028. doi: 10.1002/alz.12745. Epub 2022 Jul 19.
4
Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.血浆生物标志物水平与其 CSF 浓度及职业运动员脑震荡次数和严重程度的关系。
Neurology. 2022 Jul 26;99(4):e347-e354. doi: 10.1212/WNL.0000000000200615. Epub 2022 Jun 2.
5
Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.外周 sTREM2 相关炎症活性改变在早期阿尔茨海默病中的作用。
J Immunol. 2022 May 15;208(10):2283-2299. doi: 10.4049/jimmunol.2100771. Epub 2022 May 6.
6
Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.Tau 和神经丝轻链作为脊髓小脑共济失调 3 型的液体生物标志物。
Eur J Neurol. 2022 Aug;29(8):2439-2452. doi: 10.1111/ene.15373. Epub 2022 May 26.
7
Soluble TREM2 is associated with death and cardiovascular events after acute ischemic stroke: an observational study from CATIS.可溶性 TREM2 与急性缺血性脑卒中后死亡和心血管事件相关：来自 CATIS 的观察性研究。
J Neuroinflammation. 2022 Apr 12;19(1):88. doi: 10.1186/s12974-022-02440-y.
8
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.六种 Simoa 测定法检测血浆 P-tau 异构体 P-tau181、P-tau217 和 P-tau231 的临床和分析比较。
Alzheimers Res Ther. 2021 Dec 4;13(1):198. doi: 10.1186/s13195-021-00939-9.
9
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.用于阿尔茨海默病的血液生物标志物：迈向临床应用
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
10
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.阿尔茨海默病中 8 种血浆淀粉样蛋白β 42/40 分析物的对头比较。
JAMA Neurol. 2021 Nov 1;78(11):1375-1382. doi: 10.1001/jamaneurol.2021.3180.